DSP-2230 Capsaicin and UVB Challenge Study
| ISRCTN | ISRCTN80154838 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN80154838 |
| Protocol serial number | D8450055 |
| Sponsor | Sunovion Pharmaceuticals Europe Ltd |
| Funder | Sunovion Pharmaceuticals Europe Ltd |
- Submission date
- 28/11/2012
- Registration date
- 17/12/2012
- Last edited
- 08/06/2017
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Signs and Symptoms
Plain English summary of protocol
Background and study aims
DSP-2230 is a new drug that has shown promising results in reducing the feeling of pain. The main aim of the study is to investigate the response of the skin on experiencing pain and to assess the painkilling properties of DSP-2230 which, it is hoped, will be helpful in treating a condition called peripheral neuropathic pain.
Who can participate?
Healthy men aged 18 to 55 years.
What does the study involve?
The study is undertaken in two parts, but you will only participate in one part of the study. If you are in Part 1 you will receive an injection of capsaicin to produce a redness of the skin accompanied by pain and increased sensitivity. You will attend two screening visits before the main study starts to assess your response to two capsaicin injections 4 hours apart. The main part of the study will involve four main study periods. You will stay overnight for two nights in the Clinical Unit on each of the four study periods, followed by a morning visit on Days 3 and 4. During this time you will be randomly allocated to receive a dose of the study drug or a placebo (dummy drug) as a suspension in water or a dose of pregablin or placebo as capsules. You will also give blood and urine samples, have your vital signs measured, receive a capsaicin injection and undergo pain assessments.
In Part 2 we will use ultraviolet radiation to produce an area of redness similar to sunburn and increased sensitivity to pain. You will attend two screening visits before the main study starts to undergo ultraviolet irradiation heat pain tests, carried out using a thermode (heated metal plate) and performed on your left thigh. The main part of the study will involve four main study periods. You will stay overnight for two nights in the Clinical Unit on each of the four study periods, followed by a morning visit on Days 3 and 4. During this time you will receive a dose of the study drug or placebo as a suspension or a dose of ibuprofen lysine or placebo as capsules. You will also give blood and urine samples, have your vital signs measured and undergo the heat pain test. There will be a follow-up visit for all subjects 8-11 days after receiving the last dose of the study drug.
What are the possible benefits and risks of participating?
You will not receive any direct medical benefit from participating in this study, but a potential benefit could be the detection of an unsuspected medical condition from the tests performed. You may feel discomfort during some of the tests or experience some inconvenience. Drawing blood from your arm may cause pain, bruising, light headedness and (rarely) infection. Since DSP-2230 is an investigational drug, there may be some unexpected side effects
Where is the study run from?
This research is being run by ICON Development Solutions (UK).
When is the study starting and how long is it expected to run for?
From January to April 2013.
Who is funding the study?
The study is funded by Dainippon Sumitomo Pharma Europe Ltd.
Who is the main contact?
Dr Peter Dewland
peter.dewland2@iconplc.com
Contact information
Scientific
ICON Development Solutions
Skelton House
Manchester Science Park
Manchester
M15 6SH
United Kingdom
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised double-blind double dummy placebo-controlled single dose four-way crossover design |
| Secondary study design | Randomised cross over trial |
| Study type | Participant information sheet |
| Scientific title | A randomised, double-blind, placebo-controlled, four-way crossover, two-part study investigating the pharmacodynamic effect of DSP-2230 using the ID Capsaicin and UVB models in healthy male subjects, using pregabalin and ibuprofen lysine as positive controls. |
| Study objectives | 1. To determine the PD effects of DSP 2230 using the intradermal (ID) capsaicin model in healthy subjects 2. To determine the PD effects of DSP 2230 using the Ultraviolet B (UVB) model in healthy subjects 3. To assess the safety and tolerability of single doses of DSP 2230 in healthy subjects 4. To assess the single dose pharmacokinetics (PK) of DSP 2230 in healthy subjects 5. To assess the single dose PK/PD relationship of DSP 2230, if possible |
| Ethics approval(s) | South East Wales Research Ethics Committee |
| Health condition(s) or problem(s) studied | Peripheral Neuropathic Pain |
| Intervention | Part 1 - ID capsaicin model: ID capsaicin 100mg administered ID in 100ml of solution. Pregabalin 300 mg orally administered. Pregabalin placebo orally administered. The DSP-2230 placebo oral suspension. Part 2 - UVB model: An 800 mg dose ibuprofen (as ibuprofen lysine 342 mg, orally delivering a 200 mg dose of ibuprofen per tablet). Ibuprofen placebo orally administered. The DSP-2230 placebo oral suspension. |
| Intervention type | Drug |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Pregabalin, ibuprofen |
| Primary outcome measure(s) |
Safety: |
| Key secondary outcome measure(s) |
No secondary outcome measures |
| Completion date | 30/04/2013 |
Eligibility
| Participant type(s) | Healthy volunteer |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Male |
| Target sample size at registration | 56 |
| Key inclusion criteria | All subjects (males) will be in good health aged 18 - 55 years with no evidence of systemic disease and be able to comply with all aspects of the protocol and able to give written informed consent to participate in the study. |
| Key exclusion criteria | All subjects will not have, or have had a history of, clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, haematological or other major disorders. They will not have, or have had a history of, drug or alcohol abuse and will not have participated in a clinical study with an investigational medicinal product (IMP) within 3 months of randomisation into the current study and will not have donated or lost > 500 mL of blood or blood products in the 3 months preceding the start of dosing. |
| Date of first enrolment | 07/01/2013 |
| Date of final enrolment | 30/04/2013 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
M15 6SH
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
08/06/2017: No publications found in PubMed, verifying study status with principal investigator.
